[Clinical studies of flomoxef in the pediatric field].
Flomoxef (FMOX, 6315-S) was evaluated pharmacologically and clinically in its application to bacterial infections in children. 1. Pharmacokinetics: A bullous intravenous injection of FMOX at 20 mg/kg body weight gave a peak serum concentration of 114.6 +/- 34.4 micrograms/ml in 1 minute after the injection and T1/2 of beta-phase was 0.86 +/- 0.15 hours. 2. Bacteriological effectiveness: MIC of FMOX against Staphylococcus aureus except resistant strains (10(6) cells/ml) was below 0.39 micrograms/ml and against Haemophilus influenzae, Escherichia coli and Klebsiella pneumoniae (10(6) cells/ml) were below 0.78 microgram/ml. 3. Clinical effectiveness: Clinical effectiveness of FMOX was excellent in 14 cases, good in 2 cases and fairly good in 1 case among 17 cases of bacterial infections examined. An increase in eosinophilic leukocytes was observed in 1 case but no other clinical adverse effects were detected. These findings indicate that FMOX is a useful and safe antibiotic as a first choice against bacterial infections in children.
Morimoto
T
T
Department of Pediatrics, School of Medicine, Ehime University.
Kida
K
K
Matsuda
H
H
Murase
M
M
D000367:Age Factors; D001419:Bacteria / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D002511:Cephalosporins / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D004352:Drug Resistance, Microbial; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male
D002511:Cephalosporins; C045693:flomoxef